Key Points
- CEO Keith Sullivan sold 40,976 shares on Feb. 10 at an average price of $1.55 for $63,512.80, reducing his stake by 2.55% to 1,567,012 shares (worth ≈$2.43M).
- Large institutional buying — Goldman Sachs boosted its stake by 2,993.3% (adding 610,014 shares to 630,393), and Geode and other funds also materially increased positions, leaving institutions with about 53.6% ownership.
- Neuronetics has a market cap of ≈$108M, a 52‑week range of $1.25–$5.92 and 50‑day/200‑day moving averages of $1.68/$2.47, while analysts carry a consensus “Hold” rating with a $7.00 price target.
Neuronetics, Inc. (NASDAQ:STIM - Get Free Report) CEO Keith Sullivan sold 40,976 shares of the firm's stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $1.55, for a total value of $63,512.80. Following the transaction, the chief executive officer owned 1,567,012 shares in the company, valued at approximately $2,428,868.60. This trade represents a 2.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Neuronetics Stock Performance
NASDAQ:STIM opened at $1.58 on Friday. The company has a market cap of $108.21 million, a price-to-earnings ratio of -1.93 and a beta of 0.79. Neuronetics, Inc. has a fifty-two week low of $1.25 and a fifty-two week high of $5.92. The company has a debt-to-equity ratio of 2.09, a quick ratio of 2.09 and a current ratio of 2.24. The stock has a fifty day moving average price of $1.68 and a 200-day moving average price of $2.47.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of STIM. Goldman Sachs Group Inc. boosted its stake in shares of Neuronetics by 2,993.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 630,393 shares of the company's stock valued at $2,320,000 after purchasing an additional 610,014 shares in the last quarter. R Squared Ltd bought a new position in Neuronetics in the 2nd quarter valued at approximately $52,000. AdvisorShares Investments LLC boosted its position in Neuronetics by 8.3% in the second quarter. AdvisorShares Investments LLC now owns 130,534 shares of the company's stock valued at $456,000 after buying an additional 10,000 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors grew its stake in shares of Neuronetics by 436.2% during the second quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 86,919 shares of the company's stock worth $303,000 after buying an additional 70,709 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Neuronetics by 172.3% during the second quarter. Geode Capital Management LLC now owns 879,045 shares of the company's stock worth $3,068,000 after buying an additional 556,268 shares in the last quarter. Institutional investors and hedge funds own 53.59% of the company's stock.
Analysts Set New Price Targets
Several equities analysts have commented on STIM shares. Weiss Ratings reissued a "sell (e+)" rating on shares of Neuronetics in a report on Thursday, January 22nd. Wall Street Zen raised shares of Neuronetics from a "sell" rating to a "hold" rating in a research note on Saturday, December 6th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $7.00.
Get Our Latest Stock Report on Neuronetics
Neuronetics Company Profile
(
Get Free Report)
Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company's flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.
Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
